Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
CADL	CANDEL THERAPEUTICS INC	United States	$187.53M	29,347,468	13.72%	37.54%	Net Selling
PRME	PRIME MEDICINE INC	United States	$530.73M	119,939,247	32.55%	67.45%	Net Buying	Net Buying
NCNA	NUCANA PLC	United Kingdom	$8.46M	52,860,335	29.52%	0.00%
TELO	TELOMIR PHARMACEUTICALS INC	United States	$203.27M	29,609,814	0.00%	16.90%	Net Buying	Net Buying
MBIO	MUSTANG BIO INC	United States	$3.28M	10,390,132	9.95%	24.56%
SANA	SANA BIOTECHNOLOGY INC	United States	$1.92B	220,447,557	47.20%	52.80%	Net Buying	Net Buying
RGLS	REGULUS THERAPEUTICS INC	United States	$158.43M	65,465,251	5.87%	94.13%	Net Buying	Net Buying
KPRX	KIORA PHARMACEUTICALS INC	United States	$12.34M	26,256,197	1.15%	47.24%
RNAZ	TRANSCODE THERAPEUTICS INC	United States	$3.19M	5,808,053	12.47%	59.74%	Net Buying
ARWR	ARROWHEAD PHARMACEUTICALS INC	United States	$2.74B	123,896,914	62.55%	10.70%	Net Selling	Net Selling
LBPH	LONGBOARD PHARMACEUTICALS INC	United States	$710.26M	36,017,249	45.89%	0.09%	Net Selling
MLEC	MOOLEC SCIENCE SA	Luxembourg	$54.47M	37,563,768	0.04%	9.18%
BPTH	BIO-PATH HOLDINGS INC	United States	$1.82M	678,795	3.24%	96.76%
ERNA	ETERNA THERAPEUTICS INC	United States	$9.68M	5,410,331	0.91%	99.09%	Net Selling
AEON	AEON BIOPHARMA INC	United States	$191.59M	37,788,858	22.93%	61.40%	Net Selling
ABVC	ABVC BIOPHARMA INC	United States	$15.00M	10,560,421	0.52%	99.48%
CRBP	CORBUS PHARMACEUTICALS HOLDINGS INC	United States	$359.39M	10,493,108	5.76%	94.24%	Net Buying	Net Buying
SER	SERINA THERAPEUTICS INC	United States	$22.98M	2,500,664	12.90%	87.10%
EFTR	EFFECTOR THERAPEUTICS INC	United States	$6.97M	3,687,309	18.84%	81.16%	Net Selling
KA	KINETA INC	United States	$6.69M	10,962,460	3.86%	96.14%	Net Buying
JAGX	JAGUAR HEALTH INC	United States	$49.72M	276,216,260	0.45%	3.48%
CSBR	CHAMPIONS ONCOLOGY INC	United States	$68.24M	13,593,767	1.90%	98.10%	Net Buying
ARMP	ARMATA PHARMACEUTICALS INC	United States	$99.77M	36,148,539	1.55%	98.45%
ASLN	ASLAN PHARMACEUTICALS LTD	Singapore	$7.30M	439,926,480	0.79%	0.00%
NVAX	NOVAVAX INC	United States	$572.41M	139,953,143	55.43%	19.60%	Net Selling	Net Selling
PSTV	PLUS THERAPEUTICS INC	United States	$7.23M	4,276,082	0.60%	99.40%	Net Buying
ATRA	ATARA BIOTHERAPEUTICS INC	United States	$82.36M	119,359,230	54.24%	11.13%	Net Buying	Net Selling
ACXP	ACURX PHARMACEUTICALS INC	United States	$32.62M	15,757,102	6.93%	15.26%	Net Buying
RANI	RANI THERAPEUTICS HOLDINGS INC	United States	$335.05M	50,157,292	5.88%	51.66%	Net Buying
YS	YS BIOPHARMA CO LTD	China	$74.45M	93,058,197	10.08%	0.00%
MAIA	MAIA BIOTECHNOLOGY INC	United States	$58.81M	20,002,826	4.02%	22.12%	Net Buying	Net Buying
ELTX	ELICIO THERAPEUTICS INC	United States	$92.02M	10,235,469	3.25%	92.54%	Net Buying
ICCC	IMMUCELL CORP	United States	$39.84M	7,750,864	13.45%	24.31%	Net Buying
IBIO	IBIO INC	United States	$6.13M	3,484,266	0.72%	99.28%	Net Selling
HUMA	HUMACYTE INC	United States	$475.14M	119,083,728	14.97%	36.38%	Net Selling
GRTX	GALERA THERAPEUTICS INC	United States	$10.12M	54,392,170	23.78%	57.19%	Net Selling	Net Selling
HCWB	HCW BIOLOGICS INC	United States	$52.95M	37,823,394	2.82%	47.89%	Net Buying	Net Buying
DRMA	DERMATA THERAPEUTICS INC	United States	$2.28M	6,660,840	4.01%	95.99%
EPRX	EUPRAXIA PHARMACEUTICALS INC	Canada	N/A	27,282,165	0.00%	0.00%
ZVSA	ZYVERSA THERAPEUTICS INC	United States	$3.79M	759,486	4.63%	95.37%
ENGN	ENGENE HOLDINGS INC	Canada	$675.51M	43,581,331	32.55%	27.91%	Net Buying	Net Buying
BCLI	BRAINSTORM CELL THERAPEUTICS INC	United States	$36.49M	68,341,857	5.79%	54.09%	Net Buying	Net Buying
CLRB	CELLECTAR BIOSCIENCES INC	United States	$97.75M	32,260,510	26.67%	12.70%
QLGN	QUALIGEN THERAPEUTICS INC	United States	$1.83M	6,307,371	0.87%	99.13%
UNCY	UNICYCIVE THERAPEUTICS INC	United States	$35.80M	34,756,436	37.49%	18.00%
ENSC	ENSYSCE BIOSCIENCES INC	United States	$4.28M	7,329,172	0.72%	57.99%
CHRO	CHROMOCELL THERAPEUTICS CORP	United States	$9.40M	5,877,835	0.00%	47.70%	Net Buying	Net Buying
ALZN	ALZAMEND NEURO INC	United States	$4.94M	6,866,846	0.97%	99.03%	Net Buying	Net Buying
NRSN	NEUROSENSE THERAPEUTICS LTD	Israel	$18.92M	15,379,042	0.92%	0.00%
OTLK	OUTLOOK THERAPEUTICS INC	United States	$109.70M	13,012,876	13.26%	86.74%	Net Buying	Net Buying
PTN	PALATIN TECHNOLOGIES INC	United States	$29.37M	16,136,640	8.26%	91.74%	Net Selling	Net Selling
ACHV	ACHIEVE LIFE SCIENCES INC	United States	$157.90M	34,251,911	7.96%	27.78%	Net Selling	Net Selling
APTO	APTOSE BIOSCIENCES INC	Canada	$19.18M	15,717,701	7.58%	67.78%	Net Buying
SLS	SELLAS LIFE SCIENCES GROUP INC	United States	$82.15M	56,267,670	6.21%	13.47%	Net Selling
NRXP	NRX PHARMACEUTICALS INC	United States	$33.88M	9,569,978	6.23%	93.77%	Net Buying
ALLR	ALLARITY THERAPEUTICS INC	United States	$451.06k	308,945	4.41%	95.59%
AKTX	AKARI THERAPEUTICS PLC	United States	$18.78M	15,847,391,523	0.00%	55.06%
VCNX	VACCINEX INC	United States	$7.18M	1,231,602	18.31%	81.69%	Net Buying	Net Buying
SKYE	SKYE BIOSCIENCE INC	United States	N/A	28,062,907	0.00%	100.00%	Net Buying	Net Buying
CNSP	CNS PHARMACEUTICALS INC	United States	$2.29M	10,634,932	2.97%	5.30%	Net Buying	Net Buying
CING	CINGULATE INC	United States	$4.41M	5,010,471	0.05%	99.95%	Net Buying	Net Buying
IVA	INVENTIVA SA	France	$169.38M	52,115,807	9.33%	0.00%
ANVS	ANNOVIS BIO INC	United States	$198.31M	11,011,299	10.94%	26.91%	Net Buying
OKYO	OKYO PHARMA LTD	United Kingdom	$37.56M	25,553,274	0.15%	99.85%	Net Buying
BCTX	BRIACELL THERAPEUTICS CORP	Canada	$34.68M	15,981,726	15.42%	12.34%
VTVT	VTV THERAPEUTICS INC	United States	$81.17M	3,010,206	0.11%	99.89%	Net Buying	Net Buying
ATNF	180 LIFE SCIENCES CORP	United States	$1.53M	852,772	7.45%	92.55%	Net Buying
SCNI	SCINAI IMMUNOTHERAPEUTICS LTD	Israel	$2.00M	1,453,970,784	0.03%	0.05%
GALT	GALECTIN THERAPEUTICS INC	United States	$213.57M	61,903,672	8.36%	91.64%	Net Buying	Net Selling
CDT	CONDUIT PHARMACEUTICALS INC	United States	$234.04M	73,829,536	1.86%	73.61%
KTRA	KINTARA THERAPEUTICS INC	United States	$5.82M	39,037,899	0.62%	27.90%
ONCO	ONCONETIX INC	United States	$2.61M	22,327,701	10.85%	21.37%
RNXT	RENOVORX INC	United States	$20.96M	16,865,975	1.96%	20.25%	Net Buying
RVPH	REVIVA PHARMACEUTICALS HOLDINGS INC	United States	$83.48M	27,918,560	18.78%	38.25%
INKT	MINK THERAPEUTICS INC	United States	$32.17M	34,699,056	2.85%	72.02%	Net Buying	Net Buying
NLSP	NLS PHARMACEUTICS LTD	Switzerland	$4.89M	35,671,780	16.35%	0.00%
ICU	SEASTAR MEDICAL HOLDING CORP	United States	$33.18M	75,419,458	1.23%	19.86%	Net Buying
OCEA	OCEAN BIOMEDICAL INC	United States	$45.76M	34,149,046	13.42%	75.32%
TVGN	TEVOGEN BIO HOLDINGS INC	United States	$153.25M	153,249,359	1.50%	98.50%	Net Selling
CLDI	CALIDI BIOTHERAPEUTICS INC	United States	$5.72M	35,538,034	5.35%	49.17%	Net Selling	Net Buying
NKGN	NKGEN BIOTECH INC	United States	$36.72M	22,805,643	15.84%	84.16%	Net Buying
PBM	PSYENCE BIOMEDICAL LTD	Canada	$11.50M	13,390,659	3.69%	66.53%	Net Selling

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.72% over the past year, underperforming other biotech stocks by -8 percentage points.

Incyte has an average 1 year price target of $74.69, an upside of 44.53% from Incyte's current stock price of $51.68.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 23.08% have issued a Strong Buy rating, 23.08% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -7.45% over the past year, overperforming other biotech stocks by 15 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.33% from Harmony Biosciences Holdings's current stock price of $29.32.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 2.42% over the past year, overperforming other biotech stocks by 25 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 169.03% from Voyager Therapeutics's current stock price of $7.62.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 15.1%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)

Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 57.38%, which is 42 percentage points higher than the biotech industry average of 15.1%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)

Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.08%, which is -14 percentage points lower than the biotech industry average of 15.1%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 1.2% in the last day, and up 1.13% over the last week. Biodexa Pharmaceuticals was the among the top gainers in the biotechnology industry, gaining 79.31% yesterday.

Biodexa shares are trading higher after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -20.21% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 86 points higher than the biotech industry average of 14. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 2.42% in the past year. It has overperformed other stocks in the biotech industry by 25 percentage points.

3. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 72 points higher than the biotech industry average of 14. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.72% in the past year. It has underperformed other stocks in the biotech industry by -8 percentage points.

Are biotech stocks a good buy now?

49.23% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 91.72% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 14.88x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.